Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN Y LIU

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1164462834
CMS profile
279230
Location
ANCHORAGE, AK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$5,396.71

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,171.73 123
Consulting Fee $2,050.00 1
Education $174.98 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN Y LIU

NPI 1164462834 · CMS profile ID 279230

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ANCHORAGE, AK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN Y LIU, NPI 1164462834, CMS profile ID 279230. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). STEVEN Y LIU, NPI 1164462834, CMS profile ID 279230. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
STEVEN Y LIU, NPI 1164462834, CMS profile ID 279230, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 126 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1164462834?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $5,396.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $27.5607/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197086037 CMS
E.R. Squibb & Sons, L.L.C. $21.2207/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666650 CMS
GENZYME CORPORATION $25.5207/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233249798 CMS
ABBVIE INC. $24.0107/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202314932 CMS
ABBVIE INC. $2.4607/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202314934 CMS
Incyte Corporation $19.3407/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226157329 CMS
Regeneron Healthcare Solutions, Inc. $28.5307/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212976623 CMS
AstraZeneca Pharmaceuticals LP $29.8407/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206805617 CMS
Lilly USA, LLC $25.4007/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186911142 CMS
Rigel Pharmaceuticals, Inc. $25.9307/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247375410 CMS
E.R. Squibb & Sons, L.L.C. $25.3007/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666619 CMS
ABBVIE INC. $32.5907/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202314930 CMS
AstraZeneca Pharmaceuticals LP $24.9906/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206423345 CMS
Caris MPI, Inc. $16.6706/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234282560 CMS
E.R. Squibb & Sons, L.L.C. $6.9606/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666614 CMS
ADC THERAPEUTICS AMERICA, INC. $24.7306/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246116798 CMS
Incyte Corporation $23.9506/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226167110 CMS
Novartis Pharmaceuticals Corporation $24.4806/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755877 CMS
Daiichi Sankyo Inc. $99.9906/16/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1197087837 CMS
Apellis Pharmaceuticals, Inc. $25.9906/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253207032 CMS
Celgene Corporation $29.9206/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666560 CMS
Gilead Sciences, Inc. $18.1206/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234547727 CMS
Genentech USA, Inc. $23.6306/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211595214 CMS
BeOne Medicines USA, Inc. $13.3206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202902254 CMS
GlaxoSmithKline, LLC. $28.1005/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191296090 CMS
AstraZeneca Pharmaceuticals LP $23.7505/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206153257 CMS
Novartis Pharmaceuticals Corporation $24.1405/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755865 CMS
SpringWorks Therapeutics, Inc. $21.4905/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232164537 CMS
Caris MPI, Inc. $25.6505/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234282558 CMS
AstraZeneca Pharmaceuticals LP $55.0905/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206310702 CMS
AstraZeneca Pharmaceuticals LP $23.7905/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207012394 CMS
ARRAY BIOPHARMA INC $14.3705/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231311808 CMS
Rigel Pharmaceuticals, Inc. $32.9705/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247373258 CMS
Novartis Pharmaceuticals Corporation $14.7905/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755867 CMS
Novartis Pharmaceuticals Corporation $0.5805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755869 CMS
E.R. Squibb & Sons, L.L.C. $31.2504/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666535 CMS
Novartis Pharmaceuticals Corporation $4.4004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755863 CMS
BeOne Medicines USA, Inc. $87.6704/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202902252 CMS
GENZYME CORPORATION $31.6304/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233249784 CMS
EMD Serono, Inc. $24.5604/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236921479 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.5904/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223919550 CMS
Ipsen Biopharmaceuticals, Inc $74.9904/14/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1208825143 CMS
GlaxoSmithKline, LLC. $24.3604/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190906733 CMS
Merck Sharp & Dohme LLC $24.5804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238025958 CMS
Novartis Pharmaceuticals Corporation $21.7604/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755859 CMS
ABBVIE INC. $32.6004/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202314928 CMS
BeOne Medicines USA, Inc. $9.4403/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202902256 CMS
E.R. Squibb & Sons, L.L.C. $24.4303/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666499 CMS
E.R. Squibb & Sons, L.L.C. $23.4303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184666495 CMS
Novartis Pharmaceuticals Corporation $18.5203/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200755871 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,480.36 86
PY2020 $7,651.58 82
PY2021 $1,754.83 68
PY2022 $3,366.66 69
PY2023 $4,189.64 89
PY2024 $3,045.34 124
PY2025 $5,396.71 126

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,802.65 2
PY2025 Principal investigator $1,994,396.58 183
PY2024 Recipient $8,496.64 5
PY2024 Principal investigator $2,080,007.77 126
PY2023 Recipient $1,356.60 1
PY2023 Principal investigator $1,954,936.96 85
PY2022 Principal investigator $713,493.97 29
PY2021 Principal investigator $125,358.64 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

185 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $3,836.10 12/31/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 No dispute reported 06/30/2026 1232928936
Principal investigator 1 BeOne Medicines Ltd. $2,126.00 12/23/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190327547
Recipient F. Hoffmann-La Roche AG $1,218.32 12/12/2025 Covered Recipient Physician A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211539115
Principal investigator 1 BioNTech SE $2,200.00 12/11/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
BNT327 No dispute reported 06/30/2026 1249018804
Principal investigator 1 BioNTech SE $2,078.00 12/11/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
BNT327 No dispute reported 06/30/2026 1249018808
Principal investigator 1 BioNTech SE $12,000.00 12/11/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
BNT327 No dispute reported 06/30/2026 1249018810
Recipient F. Hoffmann-La Roche AG $584.33 12/08/2025 Covered Recipient Physician A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211539118
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,000.00 12/05/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
A Phase II Trial of BMS-986504 in Participants with Advanced and or Metastatic Non- Small Cell Lung Cancer with Homozygous MTAP Deletion After Progression on Prior Therapies No dispute reported 06/30/2026 1235999185
Principal investigator 1 Genentech, Inc. $7,450.00 12/03/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase 3 randomized mosunetuzumab with polatuzumab in comparison with R GemOx in R R NHL No dispute reported 06/30/2026 1211571017
Principal investigator 1 Daiichi Sankyo Inc. $37.60 12/01/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS1062-328 No dispute reported 06/30/2026 1223363184
Principal investigator 1 Daiichi Sankyo Inc. $94.00 12/01/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS1062-328 No dispute reported 06/30/2026 1223363186
Principal investigator 1 Daiichi Sankyo Inc. $263.20 12/01/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS1062-328 No dispute reported 06/30/2026 1223363188
Principal investigator 1 Daiichi Sankyo Inc. $51.75 12/01/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS1062-328 No dispute reported 06/30/2026 1223363190
Principal investigator 1 Daiichi Sankyo Inc. $112.80 12/01/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS1062-328 No dispute reported 06/30/2026 1223363192
Principal investigator 1 Genmab U.S., Inc. $4,000.99 11/24/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY,
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235927525
Principal investigator 1 Genmab U.S., Inc. $5,919.25 11/24/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY,
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235927530
Principal investigator 1 Genmab U.S., Inc. $1,073.25 11/24/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY,
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235927534
Principal investigator 1 BioNTech SE $8,050.00 11/20/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
BNT327 No dispute reported 06/30/2026 1249018806
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,000.00 11/19/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY, LLC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185554655
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $46.64 11/19/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998623
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.00 11/19/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998625
Principal investigator 1 Genentech, Inc. $72.00 11/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571044
Principal investigator 1 Genentech, Inc. $17,910.00 11/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571048
Principal investigator 1 Genentech, Inc. $3,828.00 11/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571052
Principal investigator 1 Genentech, Inc. $340.00 11/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571056
Principal investigator 1 Genentech, Inc. $189.00 11/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571060
Principal investigator 1 Genentech, Inc. $248.00 11/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571064
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,220.10 11/06/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology, Llc
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1235999173
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,250.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY, LLC
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185554649
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,400.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY, LLC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185554651
Principal investigator 1 Genentech, Inc. $22,873.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570938
Principal investigator 1 Genentech, Inc. $2,500.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570942
Principal investigator 1 Genentech, Inc. $22,873.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570947
Principal investigator 1 Genentech, Inc. $22,873.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570952
Principal investigator 1 Genentech, Inc. $22,873.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570956
Principal investigator 1 Genentech, Inc. $34,104.00 11/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570960
Principal investigator 1 Genentech, Inc. $1,500.00 10/29/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571029
Principal investigator 1 Genentech, Inc. $2,500.00 10/29/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571032
Principal investigator 1 Genentech, Inc. $500.00 10/29/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571036
Principal investigator 1 Genentech, Inc. $1,000.00 10/29/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571039
Principal investigator 1 Genentech, Inc. $23,982.00 10/28/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1211571067
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,167.27 10/28/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190302929
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,425.85 10/28/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190302935
Principal investigator 1 Genentech, Inc. $1,929.00 10/24/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570934
Principal investigator 1 Genentech, Inc. $4,549.00 10/17/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571013
Principal investigator 1 Genentech, Inc. $16,078.00 10/16/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL No dispute reported 06/30/2026 1211570964
Principal investigator 1 Genentech, Inc. $102,759.47 10/08/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571009
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,225.00 10/06/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220815672
Principal investigator 1 Daiichi Sankyo Inc. $1,254.00 10/02/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363339
Principal investigator 1 Daiichi Sankyo Inc. $3,500.00 10/02/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363341
Principal investigator 1 Daiichi Sankyo Inc. $1,400.00 10/02/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363343
Principal investigator 1 Mirati Therapeutics, Inc. $3,800.00 10/02/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology, Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236531292
Principal investigator 1 Novartis Pharmaceuticals Corporation $100.00 10/01/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190302931
Principal investigator 1 Merck Sharp & Dohme LLC $1,500.00 09/29/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated with Hyaluronidase MK-3475A Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types MK-3475A-F11 No dispute reported 06/30/2026 1232928892
Principal investigator 1 BeOne Medicines Ltd. $3,329.00 09/23/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190327545
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $35,000.00 09/18/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion No dispute reported 06/30/2026 1235999179
Principal investigator 1 Genentech, Inc. $1,951.00 09/12/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570925
Principal investigator 1 BeOne Medicines USA, Inc. $8,357.00 08/26/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer No dispute reported 06/30/2026 1190328571
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $33.94 08/26/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998619
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $23.32 08/26/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998621
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,305.13 08/26/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion No dispute reported 06/30/2026 1235999181
Principal investigator 1 Genmab U.S., Inc. $5,919.25 08/06/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY,
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235927521
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $31,000.00 08/04/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination with Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recurrent Non Small Cell Lung Cancer No dispute reported 06/30/2026 1235999177
Principal investigator 1 Genentech, Inc. $3,348.00 07/29/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571005
Principal investigator 1 Genentech, Inc. $1,929.00 07/09/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570930
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/18/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190337282
Principal investigator 1 BeOne Medicines Ltd. $3,329.00 06/17/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190331049
Principal investigator 1 Celgene Corporation $51,027.00 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology, Llc
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222306671
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363194
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363196
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363198
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363200
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363202
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363204
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363206
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363208
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363210
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363212
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363214
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363216
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363218
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363220
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363222
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363224
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363226
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363228
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363230
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363232
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363234
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363236
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363238
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363240
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363242
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363244
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363246
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363248
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363250
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363252
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363254
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363256
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363258
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363260
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363262
Principal investigator 1 Daiichi Sankyo Inc. $30.24 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363264
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363266
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363268
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363270
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363272
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363274
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363276
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363278
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363280
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363282
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363284
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363286
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363288
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363290
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363292
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363294
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363296
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363298
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363300
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363302
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363304
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363306
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363308
Principal investigator 1 Daiichi Sankyo Inc. $55.08 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363310
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363312
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363314
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363316
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363318
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363320
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363322
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363324
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363326
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363328
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363330
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363332
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363334
Principal investigator 1 Daiichi Sankyo Inc. $17.79 06/13/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
DS8201-793 No dispute reported 06/30/2026 1223363336
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,400.00 06/11/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY, LLC
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554653
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,140.00 06/04/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology, Llc
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations No dispute reported 06/30/2026 1235999175
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,000.00 06/03/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190311771
Principal investigator 1 Genentech, Inc. $5,526.00 06/02/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570972
Principal investigator 1 Genentech, Inc. $14,678.00 05/28/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570967
Principal investigator 1 Genentech, Inc. $54,555.00 05/14/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570994
Principal investigator 1 Genentech, Inc. $5,567.00 05/09/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570918
Principal investigator 1 Genentech, Inc. $378.00 05/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571025
Principal investigator 1 Genentech, Inc. $26,209.00 04/25/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570997
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,160.54 04/23/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
A Phase II Trial of BMS-986504 in Participants with Advanced and or Metastatic Non- Small Cell Lung Cancer with Homozygous MTAP Deletion After Progression on Prior Therapies No dispute reported 06/30/2026 1235999183
Principal investigator 1 Genentech, Inc. $8,870.00 04/22/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570984
Principal investigator 1 Genentech, Inc. $44,957.00 04/22/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570989
Principal investigator 1 BeiGene, Ltd. $3,329.00 04/17/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323954
Principal investigator 1 BeiGene, Ltd. $47,160.00 04/14/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322246
Principal investigator 1 Incyte Corporation $1,500.00 04/10/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1240500498
Principal investigator 1 Genentech, Inc. $7,980.00 04/09/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570921
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,562.00 04/04/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220815670
Principal investigator 1 Genentech, Inc. $9,786.00 04/01/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211571001
Principal investigator 1 BeiGene, Ltd. $15,720.00 03/31/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323786
Principal investigator 1 Eli Lilly and Company $264.06 03/10/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY, LLC.
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187875263
Principal investigator 1 BeiGene, Ltd. $9,099.00 02/25/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323952
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $237.58 02/25/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998609
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $104.94 02/25/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998611
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 02/25/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998613
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $73.00 02/25/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998615
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.50 02/25/2025 Non-covered Recipient Entity
Alaska Oncology And Hematology
Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours No dispute reported 06/30/2026 1220998617
Principal investigator 1 Genentech, Inc. $1,951.00 02/12/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570910
Principal investigator 1 Astellas Pharma Global Development $1,000.00 02/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234181572
Principal investigator 1 Astellas Pharma Global Development $13,550.00 02/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234181574
Principal investigator 1 Astellas Pharma Global Development $1,500.00 02/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234181576
Principal investigator 1 Genentech, Inc. $2,500.00 02/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570894
Principal investigator 1 Genentech, Inc. $2,750.00 02/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570901
Principal investigator 1 Genentech, Inc. $8,277.00 02/05/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211571021
Principal investigator 1 Novartis Pharmaceuticals Corporation $115,321.10 01/31/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190302937
Principal investigator 1 BeiGene, Ltd. $31,440.00 01/29/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323816
Principal investigator 1 BeiGene, Ltd. $12,961.00 01/28/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323948
Principal investigator 1 Genentech, Inc. $15,057.00 01/28/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570977
Principal investigator 1 Genentech, Inc. $686.00 01/28/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211570981
Principal investigator 1 BeiGene, Ltd. $2,419.00 01/21/2025 Non-covered Recipient Entity
Alaska Oncology and Hematology, LLC
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323950
Principal investigator 1 Genentech, Inc. $5,320.00 01/15/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570889
Principal investigator 1 Eli Lilly and Company $84,657.32 01/08/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY, LLC.
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187876089
Principal investigator 1 Genentech, Inc. $22,873.00 01/03/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570898
Principal investigator 1 Genentech, Inc. $22,873.00 01/03/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570906
Principal investigator 1 Genentech, Inc. $22,873.00 01/03/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211570914
Principal investigator 1 Novartis Pharmaceuticals Corporation $618,261.95 01/01/2025 Non-covered Recipient Entity
ALASKA ONCOLOGY AND HEMATOLOGY
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190302933